These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 15953827)
1. Environmental toxins and alpha-synuclein in Parkinson's disease. Liu Y; Yang H Mol Neurobiol; 2005; 31(1-3):273-82. PubMed ID: 15953827 [TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related]
3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Büeler H Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005 [TBL] [Abstract][Full Text] [Related]
4. Controlling the mass action of alpha-synuclein in Parkinson's disease. Kim C; Lee SJ J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382 [TBL] [Abstract][Full Text] [Related]
5. A new role for α-synuclein in Parkinson's disease: Alteration of ER-mitochondrial communication. Guardia-Laguarta C; Area-Gomez E; Schon EA; Przedborski S Mov Disord; 2015 Jul; 30(8):1026-33. PubMed ID: 25952565 [TBL] [Abstract][Full Text] [Related]
6. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease. Esteves AR; Gozes I; Cardoso SM Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997 [TBL] [Abstract][Full Text] [Related]
7. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Hashimoto M; Rockenstein E; Crews L; Masliah E Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050 [TBL] [Abstract][Full Text] [Related]
8. α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease. Bir A; Sen O; Anand S; Khemka VK; Banerjee P; Cappai R; Sahoo A; Chakrabarti S J Neurochem; 2014 Dec; 131(6):868-77. PubMed ID: 25319443 [TBL] [Abstract][Full Text] [Related]
9. alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease? Lee SJ Antioxid Redox Signal; 2003 Jun; 5(3):337-48. PubMed ID: 12880487 [TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein and Parkinson's disease: a proteomic view. Fasano M; Lopiano L Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054 [TBL] [Abstract][Full Text] [Related]
16. The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease. Xu Y; Deng Y; Qing H J Neurochem; 2015 Oct; 135(1):4-18. PubMed ID: 26134497 [TBL] [Abstract][Full Text] [Related]
17. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse. Perfeito R; Cunha-Oliveira T; Rego AC Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820 [TBL] [Abstract][Full Text] [Related]
18. A new perspective in Parkinson's disease, chaperone-mediated autophagy. Li B; Zhang Y; Yuan Y; Chen N Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675 [TBL] [Abstract][Full Text] [Related]
19. SUMO-regulated mitochondrial function in Parkinson's disease. Guerra de Souza AC; Prediger RD; Cimarosti H J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327 [TBL] [Abstract][Full Text] [Related]
20. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease. Bobela W; Aebischer P; Schneider BL Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]